Filing Flows › Krystal Biotech (KRYS) › Capital expenditures
Krystal Biotech (KRYS) capital expenditures by quarter
Krystal Biotech's capital expenditures were $996K in Q3 2026 (third quarter 2026), -72% from Q2 2026. Over the last 7 quarters it ranged from $996K (Q3 2026) to $7.1M (Q1 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $996K | -72% | -42% |
| Q2 2026 | $3.6M | -50% | +87% |
| Q1 2026 | $7.1M | +234% | +15% |
| Q4 2025 | $2.1M | +26% | — |
| Q3 2025 | $1.7M | -11% | — |
| Q2 2025 | $1.9M | -69% | — |
| Q1 2025 | $6.2M | — | — |
Q3 2026 at a glance
Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Krystal Biotech's capital expenditures?
Krystal Biotech's capital expenditures were $996K in Q3 2026 (third quarter 2026), -72% from Q2 2026.
How has Krystal Biotech's capital expenditures changed?
Over the last 7 quarters it ranged from $996K (Q3 2026) to $7.1M (Q1 2026).